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Abstract
Background: We aimed to create a novel modified score by combining anatomic and hemo-
dynamic Doppler-echocardiographic measures for selection of suitable patients with mitral 
stenosis for percutaneous balloon mitral valvuloplasty (PBMV) and its impact in prediction 
of outcome.
Methods: 262 consecutive patients candidate for PBMV were enrolled. Wilkins score and  
a global score based on anatomical parameters (Wilkins score, posterior to anterior mitral leaflet  
ratio [PMVL/AMVL ratio]; left atrial diameter [LAD]) and hemodynamic parameters (mitral 
regurgitation [MR]; atrioventricular compliance [CN]; systolic pulmonary artery pressure 
[SPAP]) were assessed. Patients were classified into two groups according to their outcomes.
Results: Global Echo-Doppler Score (GEDS) for patients with favorable vs. those with unfavo-
rable outcomes was (5.0 ± 0.9 vs. 8.9 ± 1.3; p < 0.001). Sensitivity, specificity, and accuracy 
of a GEDS ≥ 7 for prediction of cardiac events were 97.5%, 88%, and 97.5%, respectively. The 
area under the receiver operating characteristic curve was 0.95 (p < 0.001). The correlation 
coefficient was 0.852 (p < 0.0001) for GEDS 0.531 (p < 0.002), for Wilkins score 0.315  
(p < 0.02), for PMVL/AMVL 0.460 (p < 0.01), for LAD; MR: Pre-PBMV (r = 0.348,  
p < 0.03); CN [mL/mm Hg] (r = 0.579, p < 0.01) and SPAP [mm Hg] (r = 0.499, p < 0.01). 
In the regression analysis, GEDS, Wilkins score, and LAD were entered into the model. The 
regression coefficient (r = 0.695) of GEDS was much higher than those of the other 2 factors.
Conclusions: GEDS is an independent predictor of PBMV success and clinical outcome and 
may be formulated in a scoring system that would help to identify the proper timing and best 
candidates for PBMV. (Cardiol J 2014; 21, 2: 152–157)
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Introduction
With successful balloon mitral valvuloplasty 
(MV), there is generally a twofold increase in the 
mitral valve area (MVA) and an associated dra-
matic fall in transmitral valve gradient, left atrial 
pressure, and pulmonary artery pressure [1–4]. 
These hemodynamic benefits are associated with 
post-procedural improvement in the patients’ 
symptoms and exercise tolerance [5]. The safety 
and success of balloon MV techniques is mostly 
dependent on the selection of patients. There 
are multiple predictors of the outcome, including 
age, functional class, previous commissurotomy, 
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pre-procedure MVA, valve anatomy, and balloon 
size used [6]. Morphology of the mitral valve is 
considered the main predictor of a successful bal-
loon MV and hence, mitral valve scoring system 
using echocardiography is of crucial importance [6]. 
Many scores are derived from the targeting patient 
selection before balloon MV and they correlate 
severity with immediate and long-term outcome.
We aimed to create a novel modified score by 
combining anatomic and hemodynamic Doppler-
-echocardiographic measures for selection of sui-
table patients with mitral stenosis for percutaneous 
balloon mitral valvuloplasty (PBMV) and to inve-
stigate its impact on outcome of PBMV. We have 
called it the Global Echo-Doppler Score (GEDS). 
We believe that the GEDS will provide new insight 
into the objective risk stratification in patients with 
mitral stenosis and suitability for PBMV.
Methods
We prospectively included 262 consecutive 
patients with rheumatic mitral stenosis who were 
subjected to PBMV using multitrack technique in 
Zagazig University Hospital. Our study is confor-
med to the Helsinki Declaration. All patients gave 
their informed consents to participate in the study. 
Inclusion criteria included symptomatic mitral ste-
nosis (MS) with New York Heart Association fun-
ctional class II or more with MVA £ 1.5 cm2 and mi-
tral valve echocardiographic score £ 11 according 
to scoring system described by Wilkins et al. [7]. 
Exclusion criteria were patients with mitral re-
gurgitation (MR) or aortic regurgitation of gra- 
de II/IV or more, also, patients with Wilkins scoring 
of > 11 [7] and presence of left atrial (LA) thrombi 
assessed by trans-esophageal echocardiography.
Echocardiographic and  
Doppler examinations
Comprehensive 2-dimensional (2D) and color 
Doppler transthoracic echocardiogram was perfor-
med before PBMV. The morphologic features of the 
mitral valve were categorized using the Wilkins 
echo score [7] and the total echocardiographic sco-
re was obtained by adding the scores of leaflet mo-
bility, thickness, calcification, and sub-valvular le-
sions. The structure of the valve and the sub-valvar 
apparatus were imaged in the parasternal long-axis 
and apical 4-chamber views. Furthermore, maxi-
mal leaflet lengths of MV leaflets were measured 
in the parasternal long-axis view at end-diastole, 
then a posterior to anterior mitral valve leaflets 
length (PMVL/AMVL) ratio was calculated [8]. 
LA diameter was measured, and continuous wave 
Doppler was used to calculate peak pressure 
gradient of tricuspid regurgitation. Mitral and 
tricuspid regurgitations were graded from 0 to 
4+, depending on the spatial extent of the color 
flow jet area expressed as percentage of the left 
or right atrial area. Patients were screened for LA 
thrombus with a 2D trans-esophageal echocardio-
gram in 24 h preceding the procedure. If thrombus 
was detected, the patient was not a candidate 
for PBMV. Doppler velocity tracings were re-
corded at a speed of 100 mm/s. The duration 
of the diastolic filling period and maximal and 
mean trans-mitral pressure gradients (Bernoulli 
equation) were obtained from the continuous-
-wave Doppler signal of mitral flow velocity. 
Stroke volume was calculated as left ventricular 
outflow tract area multiplied by the time inte-
gral of the outflow tract velocity (pulsed-wave 
Doppler). Outflow tract area was determined as 
D2p/4, where D is its diameter measured from 
a zoomed systolic freeze-frame in the parasternal 
long-axis view. With the continuity equation, MVA 
was calculated as stroke volume divided by mitral 
time-velocity integral [9, 10]. Severity of MR was 
determined by expressing the ratio of maximal jet 
area to LA area in the same view using color flow 
mapping and graded from 1 to 4 [11]. Systolic pul-
monary artery pressure (SPAP) was derived from 
the tricuspid regurgitant jet velocity (v) with the 
modified Bernoulli equation (4v2) and assuming 
a right atrial pressure of 10 mm Hg [12].
Calculation of net atrioventricular  
compliance
Atrioventricular compliance (CN) can be calcu-
lated from the deceleration rate (dV/dt) of the mitral 
velocity profile (E-wave downslope) and effective 
MVA, determined by the continuity equation, as 
demonstrated by Flachskampf et al. [13]:
CN = 1270 (MVA/E-wave downslope)
Where CN is obtained in cm3/mm Hg (mL/mm Hg) 
if MVA is expressed in cm2 and the E-wave 
downslope in cm/s2. CN was assessed only from 
the resting measurements, and the E-wave down-
slope (curvilinear in 2 cases) was determined by 
the average slope method.
Description of the scoring system
A scoring system designed by us was used in 
accordance with the multiple indices mentioned 
above (Table 1).
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The score value for Wilkins score is 1 or 
2 points according to severity (£ 8 or > 8). Score 
values for LA diameter is 1 or 2 points according 
to the degree of LA dilatation (£ 5 cm or > 5 cm), 
PMVL/AMVL ratio 1 or 2 points according to the 
ratio (≥ 1/2 or < 1/2 cm2), SPAP are 1 or 2 points 
for (< 50 mm Hg or ≥ 50 mm Hg), score for CN 
is 1 or 2 points according to the value (£ 4.0 mL/ 
/mm Hg or > 4.0 mL/mm Hg) and a score of 0, 1 or 
2 for the presence and degree of MR. The totals, 
when scores for all factors are added, constitute 
the GEDS.
Clinical and echocardiographic follow-up
A detailed clinical and echocardiographic (2D, 
continuous-wave Doppler and color-flow imaging) 
assessment was conducted at every 3 months for 
the first year and at 6-month intervals thereafter, 
with a median duration of 28 (range 12–42) months. 
The predefined study endpoints were assessed: 
a composite clinical events endpoint including 
cardiovascular death, mitral valve re-intervention, 
newly developed atrial fibrillation (AF), progressi-
ve re-elevation of pulmonary artery pressure, 
and hospital admission due to decompensated 
heart failure. The patients were divided into two 
groups (favorable and unfavorable) according to 
clinical events and the need for post-PBMV mitral 
re-intervention.
Statistical analysis
All continuous variables are reported as mean 
± SD or as percentages. Analysis was done with 
SPSS 16.0 (SPSS, an IBM company; Chicago, Ill). 
Receivers operating characteristic (ROC) curves 
were used to evaluate the sensitivity and speci-
ficity of GEDS for predicting cardiac events after 
PBMV. Associations of GEDS and echocardiograp-
hic parameters with outcomes were evaluated 
by use of the Spearman correlation coefficient. 
Independent predictors of GEDS were determined 
by means of multiple regression analysis, with 
candidate variables added to a model containing 
GEDS as the dependent variable and Wilkins sco-
re and LA diameter as covariates. Standardized 
b regression coefficients and their significance 
as determined by multilinear regression analysis 
were reported.
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CN — atrioventricular compliance; MR — mitral regurgitation; 
PBMV — percutaneous balloon mitral valvuloplasty; PMVL/AMVL 
ratio — posterior mitral valve leaflet to anterior mitral valve leaflet; 
SPAP — systolic pulmonary artery pressure
Table 2. Baseline demographic and echocardio-
grapic data of patients with mitral stenosis inclu-
ded in the study.
Age [years] 34.2 ± 13.5
Male/female 107/155
Body surface area [m2] 1.62 ± 0.83
AF rhythm 31/262
NYHA class 2.5 ± 0.7
Systolic BP [mm Hg] 119 ± 11
Diastolic BP [mm Hg] 70 ± 8
Echo-score 8.4 ± 1.9
MVA — 2D planimetry [cm2] 0.91 ± 0.28
MVA — PHT [cm2] 1.09 ± 0.21
Mean transmitral gradient [mm Hg] 16.4 ± 5.2
LA antero-posterior diameter [mm] 49.9 ± 0.57
LVEDD [mm] 42.8 ± 3.6
LVESD [mm] 28.5 ± 3.2
LVEF [%] 69.2 ± 10.5
RV diastolic diameter [mm] 31.1 ± 1.4
SPAP [mm Hg] 69.5± 23.8
MR grade 0.85 ± 0.71
CN [mL/mm Hg] 4.6 ± 1.9
AF — atrial fibrillation; BP — blood pressure; NYHA — New York 
Heart Association; MVA — mitral valve area; 2D — two-dimen-
sional; PHT — pressure half time; LA — left atrium; LVEDD — left 
ventricular end diastolic diameter; LVESD — left ventricular end 
systolic diameter; LVEF — left ventricular ejection fraction;  
RV — right ventricular; SPAP — systolic pulmonary artery pres-
sure; MR — mitral regurgitation; CN — atrioventricular compliance
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Results
The demographic and echocardiographic data 
are presented in Table 2. The echocardiographic 
variables in patients with MS were significantly 
improved after PBMV (Table 3). During follow-
-up, 8 patients showed worsening of MR, 29 pa-
tients showed newly developed AF, 33 patients 
showed progressive re-elevation of pulmonary 
artery pressure and, 9 underwent repeat PBMV; 
1 patient underwent valve replacement. In addition, 
8 hospital admissions due to decompensated heart 
failure were recorded. No death was recorded. 
Table 4 shows a comparison between patients with 
favorable vs. those with unfavorable outcomes 
after PBMV. The mean GEDS scores for patients 
with cardiac events vs. those without events were 
(5.0 ± 0.9 vs. 8.9 ± 1.3, respectively, p < 0.001).
The ability of GEDS to predict patients with 
cardiac events was evaluated by means of ROC 
analysis (Fig. 1). The area under the ROC curve 
was 0.95 (95% confidence interval 0.93–0.98, 
p < 0.001). A GEDS value ≥ 7 had a sensitivity 
of 97.5%, a specificity of 88%, and an accuracy of 
97.5% for predicting cardiac events. Table 5 shows 
the univariate and multivariate relationships of 
GEDS and echocardiographic parameters to cardiac 
events during follow-up. In Spearman analysis, 
statistically significant correlations were found 
between GEDS and other echocardiographic para-
meters. The correlation coefficient of GEDS was 
0.852 (p < 0.001), greater than that of the Wilkins 
score (r = 0.531, p < 0.002); MVA (r = 0.315, 
p < 0.004); LA diameter (r = 0.460, p < 0.002); 
MR: Pre-PBMV (r = 0.348, p < 0.004); CN 
(r = 0.579, p < 0.002) and SPAP (r = 0.499, 
Table 4. Comparison between patients with favorable vs. those with unfavorable outcomes after per-
cutaneous balloon mitral valvuloplasty.
Variable Favorable outcome  
group (n = 174)
Unfavorable outcome 
group (n = 88)
P
Age [year] 32.9 ± 11.5 33.2 ± 13 > 0.05
LA diameter [mm] 48.6 ± 14 52.0 ± 13 < 0.05
PMVL/AMVL ratio [cm2] 0.62 ± 0.02 0.32 ± 0.03 < 0.01
Wilkins score 8.2 ± 1.2 8.9 ± 1.1 < 0.01
Transmitral mean PG 16.2 ± 2.2 18.2 ± 2.5 > 0.05
Right ventricular diameter [mm] 29 ± 4 30 ± 2 > 0.05
Pre-procedure MR 0.8 ± 0.6 0.9 ± 0.3 > 0.05
SPAP [mm Hg] 48.3 ± 11.5 66.5 ± 12.7 < 0.01
CN [mL/mm Hg] 5.5 ± 0.7 3.1 ± 0.4 < 0.001
Global Echo-Doppler Score 5.0 ± 0.9 8.9 ± 1.3 < 0.001
LA — left atrial; PMVL/AMVL — posterior mitral valve leaflet to anterior mitral valve leaflet; PG — pressure gradient; MR — mitral regurgitation; 
SPAP — systolic pulmonary artery pressure; CN — atrioventricular compliance
Table 3. Echocardiographic variables before and immediately after percutaneous balloon mitral 
valvulo plasty (PBMV).
Variable Before PBMV After PBMV P
MVA — 2D planimetry [cm2] 0.91 ± 0.28 1.89 ± 0.24 < 0.001
MVA — PHT [cm2] 1.09 ± 0.21 2.09 ± 0.13 < 0.001
Mean transmitral gradient [mm Hg] 16.4 ± 5.2 4.5 ± 2.1 < 0.0001
LA antero-posterior diameter [mm] 49.9 ± 0.57 44.1 ± 0.2 < 0.02
LVEDD [mm] 42.8 ± 3.6 42.9 ± 0.9 > 0.05
LVESD [mm] 28.5 ± 3.2 27.3 ± 0.8 > 0.05
LVEF [%] 69.2 ± 10.5 68.9 ± 9.5 > 0.05
RV diastolic diameter [mm] 31.1 ± 1.4 26.7 ± 0.8 < 0.02
SPAP [mm Hg] 69.5 ± 23.8 38.2 ± 17.9 < 0.001
MVA — mitral valve area, 2D — two-dimensional; PHT — pressure half time; LA — left atrium; LVEDD — left ventricular end diastolic diameter; 
LVESD — left ventricular end systolic diameter; LVEF — left ventricular ejection fraction; RV — right ventricular; SPAP — systolic pulmonary 
artery pressure
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p < 0.002). In multiple linear regression analysis, 
GEDS, Wilkins score, and LA diameter were added 
to the model (p < 0.001); no other parameters were 
added. The standardized regression coefficient 
(r = 0.695) of GEDS was much higher than those 
of Wilkins score and LA diameter, 0.375 and 0.242, 
respectively, which suggested that GEDS was 
a powerful independent predictor of cardiac events 
after PBMV.
Discussion
Our results have shown that GEDS deri-
ved from both anatomic and hemodynamic echo-
Table 5. Univariate and multivariate relationships of Global Echo-Doppler Score (GEDS) and echocar-
diographic parameters to cardiac events.
Variable Spearman coefficient P Standardized RC P
Wilkins score 0.531 < 0.002 0.375 < 0.004
MVA [cm2] 0.315 < 0.02 —
LA diameter [mm] 0.460 < 0.01 0.242 < 0.004
MR: Pre-PBMV 0.348 < 0.03 —
CN [mL/mm Hg] 0.579 < 0.01 —
SPAP [mm Hg] 0.499 < 0.01 —
GEDS 0.852 < 0.0001 0.695 < 0.001
RC — regression coefficient; MVA — mitral valve area; LAD: LA — left atrial; MR — mitral regurgitation; PBMV — percutaneous balloon mitral 
valvuloplasty; CN — atrioventricular compliance; SPAP — systolic pulmonary artery pressure
Figure 1.  Receiver operating characteristic (ROC) curve 
of sensitivity and specificity of global echo-Doppler sco-
re in predicting cardiac events after percutaneous bal-
loon mitral valvoplasty. The area under the curve was 
0.95 (p < 0.001).
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-Doppler indices can predict clinical outcome of 
PBMV in patients with MS. The rise in GEDS 
correlates with unfavorable outcome at follow-up. 
GEDS in patients with unfavorable outcomes often 
exceeds 7 points.
For a proper selection of therapeutic strategy 
in patients with MS, clinical evaluation and as-
sessment of MV anatomy are essential [14–16]. 
Transthoracic 2D echocardiography allows clas-
sification of patients into anatomic groups to 
predict immediate and long-term outcome [17, 
18]. Although most cardiologists use the Wilkins 
score, several echocardiographic scoring systems 
have been suggested for evaluation of MV anatomy 
[19–22]. None of the available scores has been 
shown to be superior to any of the others [23].
The current study shows that the correlation 
coefficient of GEDS was greater than that of the 
Wilkins score. In multiple linear regression ana-
lysis, the standardized regression coefficient of 
GEDS was much higher than those of Wilkins score 
and LA diameter, which suggested that GEDS was 
a powerful independent predictor of cardiac events 
after PBMV for patients with MS.
In the selection of patients for PBMV, the 
echocardiographic assessment of the MV morp-
hology plays a crucial role [24–27] and it is now 
performed routinely in most centers. The Wilkins 
score is one of the most widely used echocardio-
graphic scoring systems [24, 26, 28, 29] and it 
provides a semi-quantitative assessment of mitral 
leaflets thickening, mobility, calcification, and 
the extent of the sub-valvular apparatus disease. 
A favorable Wilkins score (< 8 points) is highly 
predictive of an optimal outcome after PBMV [24, 
27, 29]. Nevertheless, there are studies which 
have questioned the precision of this score as 
a predictor of the outcome and have suggested the 
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need for more refined and comprehensive echocar-
diographic assessments [28, 30, 31]. Many patients 
with MS may have limited symptoms despite 
unimpressive findings. When resting gradients and 
SPAP do not reflect the real severity of the disease, 
a dynamic evaluation becomes necessary. Valvular 
capacity exhaustion should be tested on a dynamic 
background, as no single resting index can predict 
potential hemodynamic adaptation to exercise. In 
such context, the contribution of exercise echo-
cardiography remains extremely valuable [32]. But 
the assessment of hemodynamic consequences of 
MS noninvasively is simpler and more valuable for 
prognostic implication.
Nunes et al. [33], in a wide spectrum of se-
verity of MS, demonstrated that CN is a powerful 
predictor of adverse outcome, adding incremental 
prognostic value to clinical data and MVA. In ad-
dition, CN was a determinant factor of pulmonary 
hypertension, which was independent of the MS 
severity.
Conclusions
GEDS derived from combined anatomic and 
hemodynamic echocardiographic variables is an in-
dependent predictor of PBMV success and clinical 
outcome and could be formulated in a scoring sy-
stem that would help to identify the proper timing 
and best candidates for PBMV.
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